Dél-pesti Centrumkórház – Országos Hematológiai és Infektológiai Intézet, Onkológiai Osztály, Budapest
In the past decade, significant progress has been made in the understanding and treatment of cancers with BRCA mutation. Germline and somatic mutations of the BRCA1 and BRCA2 genes have prognostic and predictive value. The introduction and use of PARP inhibitors in everyday oncology care has changed the standard of pancreatic, prostate and ovarian cancer care. However, the continued improvement of the treatment of BRCA-mutated tumors is critical. Fortunately, new therapeutic targets and new treatment strategies are on the horizon. In our present work, we highlight the research that has deepened our biological and molecular knowledge of BRCA-mutant tumors, which shed light on the background of the disease and enabled effective new treatment approaches. Ongoing basic, translational and clinical research has brought change and promises new changes in the field of BRCA-deficient cancers.